Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBIT Margin: 2013-2025

Historic EBIT Margin for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to -32.29%.

  • Theravance Biopharma's EBIT Margin rose 3195.00% to -32.29% in Q3 2025 from the same period last year, while for Sep 2025 it was -40.85%, marking a year-over-year increase of 2876.00%. This contributed to the annual value of -72.92% for FY2024, which is 2466.00% up from last year.
  • Theravance Biopharma's EBIT Margin amounted to -32.29% in Q3 2025, which was down 210.41% from -10.40% recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's EBIT Margin ranged from a high of -10.40% in Q2 2025 and a low of -1,540.08% during Q1 2022.
  • Its 3-year average for EBIT Margin is -80.45%, with a median of -64.25% in 2024.
  • As far as peak fluctuations go, Theravance Biopharma's EBIT Margin skyrocketed by 424,331bps in 2021, and later plummeted by 95,165bps in 2022.
  • Over the past 5 years, Theravance Biopharma's EBIT Margin (Quarterly) stood at -375.80% in 2021, then soared by 25,680bps to -119.00% in 2022, then spiked by 8,347bps to -35.53% in 2023, then slumped by 1,353bps to -49.06% in 2024, then soared by 3,195bps to -32.29% in 2025.
  • Its EBIT Margin was -32.29% in Q3 2025, compared to -10.40% in Q2 2025 and -93.80% in Q1 2025.